Related Experiment Videos
Drug-induced liver disease
1Division of Gastroenterology, Georgetown University Medical Center, Washington, DC 20007, USA.
Current Opinion in Gastroenterology
|February 11, 2005
Summary
Drug-induced liver injury remains a significant concern, with new hepatotoxins identified and established risks like acetaminophen overdose persisting. Careful assessment and management are crucial for preventing liver damage from medications.
Area of Science:
- Hepatology
- Clinical Pharmacology
- Toxicology
Background:
- Drug-induced liver injury (DILI) remains a critical clinical challenge.
- New potential hepatotoxins and confirmed risks of existing agents were highlighted in 2002.
- Chronic viral hepatitis B and C are significant risk factors for liver injury in specific patient populations.
Purpose of the Study:
- To review recent advancements in understanding and managing drug-induced liver disease.
- To discuss the evolving definitions of liver injury and
Main Methods:
- Literature review of hepatotoxicity reports and clinical studies.
- Analysis of causality assessment in drug-induced liver disease.
- Examination of risk factors and management strategies for specific drug toxicities.
Main Results:
- Several new agents were identified as potential hepatotoxins, and existing ones were further confirmed.
- Acetaminophen (paracetamol) remains the leading cause of acute liver failure in the US and globally.
- Lowering alanine aminotransferase (ALT) thresholds may necessitate redefining "normal" liver function tests.
Conclusions:
- Refined causality assessment is vital for accurate DILI diagnosis.
- Management strategies for acetaminophen overdose and the use of hepatotoxic drugs in patients with pre-existing liver conditions require careful consideration.
- Understanding risk factors like viral hepatitis and alcohol consumption is key to preventing liver injury.